Albusomatropin

Summary

Albusomatropin (CHEMBL4298125) is a phase-3 clinical-stage unknown; indicated across 1 condition including pituitary dwarfism.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298125
Name	Albusomatropin
Type	Unknown
Max phase	3

Also known as: Albusomatropin, Albusomatropina, Albusomatropine, Albutropin, Somatropin-albumin fusion protein, Tv-1106, ALBUSOMATROPIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pituitary dwarfism	3	MONDO:0006909	EFO:1001109

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02410343	PHASE3	TERMINATED	Study of TV-1106 in Growth Hormone-Deficient Adults
NCT02410356	PHASE3	TERMINATED	Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
NCT01811576	PHASE2	COMPLETED	Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
NCT02092077	PHASE2	TERMINATED	A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).